Paclitaxel

製品コードS1150 別名:NSC 125973

Paclitaxel化学構造

分子量(MW):853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 44820.00

カスタマーフィードバック(5)

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

  • Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

    Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

  • Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NF\1UYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LUfmlEPTB;MD6wNFAzQDdizszN NGO3dHpUSU6JRWK=
LC-2-ad MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMECwN|E4KM7:TR?= NI[2bodUSU6JRWK=
RL95-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLGcml7UUN3ME2wMlAxODZ4ODFOwG0> MUDTRW5ITVJ?
MZ1-PC MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[3NVNKSzVyPUCuNFAxPzJ7IN88US=> MmW0V2FPT0WU
TE-8 Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMECxNVch|ryP MYLTRW5ITVJ?
SW954 NH;aTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\1eXBNUUN3ME2wMlAxOTF7IN88US=> NWq5V44xW0GQR1XS
TE-11 NUK0NZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLBb2ZKSzVyPUCuNFAyOjNizszN NGj2bnlUSU6JRWK=
PSN1 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDFUYJKUUN3ME2wMlAxOTNizszN NF3LOWRUSU6JRWK=
MOLT-4 MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjpTWM2OD1yLkCwNVQ6KM7:TR?= MV;TRW5ITVJ?
697 NXjDU4NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP2T2NKUUN3ME2wMlAxOTVizszN Ml35V2FPT0WU
ETK-1 NIe3TFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMECxOVIh|ryP Ml;JV2FPT0WU
TE-10 M4HSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnxNXhKSzVyPUCuNFAyPTRizszN NYL1PJY{W0GQR1XS
HUTU-80 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPORm9KSzVyPUCuNFAyPjhizszN NVXUPGNjW0GQR1XS
NTERA-S-cl-D1 M1\PVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjrTWM2OD1yLkCwNlA6KM7:TR?= MnP6V2FPT0WU
MFH-ino NUHZVXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMECyOlgh|ryP NYL5cIlRW0GQR1XS
IA-LM MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\QenN5UUN3ME2wMlAxOjhizszN M{nlW3NCVkeHUh?=
MC116 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL6eY1IUUN3ME2wMlAxOjh7IN88US=> MWXTRW5ITVJ?
RKO NFLBVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMECyPVgh|ryP NX3zOZNCW0GQR1XS
MRK-nu-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoOzTWM2OD1yLkCwNlk6KM7:TR?= MVPTRW5ITVJ?
VA-ES-BJ NILTd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHPNJpKSzVyPUCuNFA{KM7:TR?= Ml3aV2FPT0WU
KALS-1 NX:1PGZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrkWpRKSzVyPUCuNFA{ODhizszN MUXTRW5ITVJ?
BB30-HNC NGPTOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPHTWM2OD1yLkCwN|E1KM7:TR?= M2DySXNCVkeHUh?=
ACN NUTQVJUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrQbId{UUN3ME2wMlAxOzF4IN88US=> MX\TRW5ITVJ?
TE-9 NUHCSo9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMECzNlYh|ryP M3yzb3NCVkeHUh?=
SIG-M5 M3;xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLUVFR1UUN3ME2wMlAxOzJ5IN88US=> NGfPWJFUSU6JRWK=
no-10 M1juSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rIPGlEPTB;MD6wNFM3OiEQvF2= NFLVeZBUSU6JRWK=
EW-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3hWWpKUUN3ME2wMlAxOzdzIN88US=> NVrTeY4xW0GQR1XS
SK-LMS-1 NVnBbFVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMEC0NFEh|ryP M{LrOHNCVkeHUh?=
GT3TKB MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnyZmdKSzVyPUCuNFA1OzRizszN MoPIV2FPT0WU
ES4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEC0OFkh|ryP M3jOOXNCVkeHUh?=
IMR-5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT6RlNKSzVyPUCuNFA1PSEQvF2= MoHNV2FPT0WU
NCI-H1648 NVLKOFc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEC0Olkh|ryP M1HF[3NCVkeHUh?=
MV-4-11 Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET6SIRKSzVyPUCuNFA1PzVizszN NGfGeYtUSU6JRWK=
SK-UT-1 NYnlZpJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\CTWM2OD1yLkCwOFgh|ryP MYrTRW5ITVJ?
NB13 M1m5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r3fGlEPTB;MD6wNFQ6OSEQvF2= NVzCd|IxW0GQR1XS
DJM-1 NWDmS|FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHJb|ZlUUN3ME2wMlAxPTNizszN M3Tqe3NCVkeHUh?=
ES8 NVPXRpZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fJS2lEPTB;MD6wNFU{QCEQvF2= NGXEOnNUSU6JRWK=
TE-6 M37v[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTyOHlKSzVyPUCuNFA2PyEQvF2= NV3aNXlFW0GQR1XS
KS-1 MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TKd2lEPTB;MD6wNFU5OiEQvF2= MVXTRW5ITVJ?
TE-1 M4LEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmi3TWM2OD1yLkCwOlA3KM7:TR?= MYHTRW5ITVJ?
ATN-1 NFT5c3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf0XXVmUUN3ME2wMlAxPjB7IN88US=> MWrTRW5ITVJ?
A4-Fuk NHLsN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMEC2NVEh|ryP MXLTRW5ITVJ?
ALL-PO MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjxe5VKSzVyPUCuNFA3OyEQvF2= MWTTRW5ITVJ?
BE-13 M2qw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEC2N|Yh|ryP MlTTV2FPT0WU
KM12 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEC2N|ch|ryP MULTRW5ITVJ?
NOS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMEC2OUDPxE1? M4nWc3NCVkeHUh?=
SW962 NInZOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP2TWM2OD1yLkCwOlYzKM7:TR?= MY\TRW5ITVJ?
OCUB-M NHPuWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjE[GVtUUN3ME2wMlAxPjZ{IN88US=> NIrMfJJUSU6JRWK=
NCI-H510A Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\BW2lEPTB;MD6wNFY3PSEQvF2= NWDtNplmW0GQR1XS
EW-16 M4ezTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPu[lhzUUN3ME2wMlAxPjl2IN88US=> MWXTRW5ITVJ?
KGN M3;J[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDSTWM2OD1yLkCwO|EzKM7:TR?= MWfTRW5ITVJ?
LS-411N NG\pXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMEC3NVch|ryP MoDnV2FPT0WU
Becker MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLkOGdWUUN3ME2wMlAxPzJizszN M2riOnNCVkeHUh?=
HC-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnveZpsUUN3ME2wMlAxPzJzIN88US=> NVvlXlR{W0GQR1XS
CESS NYjLdmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXETWM2OD1yLkCwO|M4KM7:TR?= MljRV2FPT0WU
KURAMOCHI M1rWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\NRlRKSzVyPUCuNFA4PDhizszN MWPTRW5ITVJ?
TGBC24TKB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvoN5lKSzVyPUCuNFA4PTJizszN NYDWNIZOW0GQR1XS
SW982 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEC3OlYh|ryP NW\hNWxOW0GQR1XS
HCE-4 Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\uTXNOUUN3ME2wMlAxPzZ5IN88US=> M2PhOHNCVkeHUh?=
LOUCY MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXmendKSzVyPUCuNFA4PzVizszN M1m1ZXNCVkeHUh?=
8-MG-BA NHLRVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKxZ2FlUUN3ME2wMlAxPzl4IN88US=> MYLTRW5ITVJ?
HT-144 NUfIZVBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW5bYpKSzVyPUCuNFA5KM7:TR?= M{XWbnNCVkeHUh?=
LXF-289 NG\RdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzXOHNKSzVyPUCuNFA5OThizszN M3e3eXNCVkeHUh?=
RS4-11 MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m3Z2lEPTB;MD6wNFg{PiEQvF2= MYrTRW5ITVJ?
DEL NXfUTWxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEC4OFUh|ryP NVH1TYlGW0GQR1XS
OCI-AML2 M3HTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC5PFdGUUN3ME2wMlAxQDV{IN88US=> MnvxV2FPT0WU
CCRF-CEM MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnsTWM2OD1yLkCwPFcyKM7:TR?= MYXTRW5ITVJ?
A388 M2fHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEC4O|Qh|ryP MlTzV2FPT0WU
KNS-42 NEnlTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:4bXhKSzVyPUCuNFA5QTFizszN MUfTRW5ITVJ?
OVCAR-4 NES4VmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEC5NFQh|ryP MV7TRW5ITVJ?
NCI-H1355 Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTmSpJYUUN3ME2wMlAxQTF2IN88US=> NHHyZ4ZUSU6JRWK=
BL-70 NEW1T3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHSeFhKSzVyPUCuNFA6OyEQvF2= M3fMbHNCVkeHUh?=
BL-41 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUWyXWIxUUN3ME2wMlAxQTN2IN88US=> MUfTRW5ITVJ?
A101D M1fEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL3TWM2OD1yLkCwPVYh|ryP MoXLV2FPT0WU
HL-60 MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfFR5JpUUN3ME2wMlAxQTZ4IN88US=> MYfTRW5ITVJ?
COR-L279 NWfDe5M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOwV29KSzVyPUCuNFA6QTlizszN M1HESnNCVkeHUh?=
NCI-SNU-16 NGO1To9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfYZ2pKSzVyPUCuNFExODhizszN NHzwUo5USU6JRWK=
Calu-6 M1XsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEGwNVIh|ryP MXPTRW5ITVJ?
SR NITsSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzjO5FKSzVyPUCuNFExOjZizszN M3jYZnNCVkeHUh?=
QIMR-WIL NYmydYNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHZSHlYUUN3ME2wMlAyODN|IN88US=> M4Gzb3NCVkeHUh?=
LB647-SCLC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm3TWM2OD1yLkCxNFUyKM7:TR?= MXfTRW5ITVJ?
RPMI-8226 M2DETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEGxNFIh|ryP NYqxfmpXW0GQR1XS
SK-PN-DW NGfp[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMEGxNVIh|ryP NYXQTVZUW0GQR1XS
SF268 NF7F[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jTVmlEPTB;MD6wNVE2OSEQvF2= M{WzXHNCVkeHUh?=
HD-MY-Z NGn2UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPrRXE{UUN3ME2wMlAyOTZ|IN88US=> Mn;mV2FPT0WU
DOHH-2 NFPId2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHh[YNKSzVyPUCuNFEzODNizszN Mn65V2FPT0WU
SCC-3 NY\5XFdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Dpe2lEPTB;MD6wNVIxPCEQvF2= NH\6TnFUSU6JRWK=
ST486 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMEGyNFQh|ryP NV\DbFFbW0GQR1XS
NALM-6 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPYTWM2OD1yLkCxNlE1KM7:TR?= M33ScHNCVkeHUh?=
NCI-H1436 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMEGyN|Eh|ryP NITsfpBUSU6JRWK=
KE-37 NXrRTmxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DGPGlEPTB;MD6wNVI{PCEQvF2= NY\LOHRJW0GQR1XS
RPMI-8402 MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXaTWM2OD1yLkCxNlU3KM7:TR?= MkDpV2FPT0WU
RXF393 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMEGyOVch|ryP MnPyV2FPT0WU
KARPAS-45 NFjlVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnFTWM2OD1yLkCxNlch|ryP MVrTRW5ITVJ?
HOP-62 NWiz[XFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS3TWM2OD1yLkCxNlc3KM7:TR?= MXrTRW5ITVJ?
ES1 M1zlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjvcZpwUUN3ME2wMlAyOjh6IN88US=> MXPTRW5ITVJ?
L-363 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HUbWlEPTB;MD6wNVM2OSEQvF2= NHTTZnhUSU6JRWK=
GI-1 M1\ZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDsc5VKSzVyPUCuNFE{PzNizszN Mo\4V2FPT0WU
CTV-1 NH3hOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\STWM2OD1yLkCxOFc5KM7:TR?= MYDTRW5ITVJ?
TE-5 NIftenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX0cY1KSzVyPUCuNFE1QTZizszN M1L5b3NCVkeHUh?=
SNU-C2B NUfnd2M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL6NoFDUUN3ME2wMlAyPDl4IN88US=> MWDTRW5ITVJ?
K-562 NHfPR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PLTGlEPTB;MD6wNVUyPiEQvF2= NWXKe3E5W0GQR1XS
SNB75 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXWfYFKSzVyPUCuNFE2PCEQvF2= M4XEc3NCVkeHUh?=
MOLT-13 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHnTWM2OD1yLkCxOlM4KM7:TR?= Ml3tV2FPT0WU
LS-123 M1TYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWntWm9TUUN3ME2wMlAyPjZ2IN88US=> MYHTRW5ITVJ?
NCI-SNU-5 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDpTWM2OD1yLkCxO|AyKM7:TR?= NUXre3YzW0GQR1XS
Daudi MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMEG3NFgh|ryP M{\Ic3NCVkeHUh?=
A253 M3;lWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T0VGlEPTB;MD6wNVc{QCEQvF2= MmjNV2FPT0WU
TGBC1TKB NV3MXYF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nKUGlEPTB;MD6wNVc2OiEQvF2= MljhV2FPT0WU
SJSA-1 MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfCNmdpUUN3ME2wMlAyPzZ5IN88US=> Mn\ZV2FPT0WU
NCCIT NVLCfHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDHfHFKSzVyPUCuNFE4PjlizszN M4HhbHNCVkeHUh?=
NCI-H69 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7FcWZKSzVyPUCuNFE4PzhizszN NEfHSWdUSU6JRWK=
SH-4 NGj6SHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHxTWM2OD1yLkCxPFk2KM7:TR?= NYm2WJZGW0GQR1XS
HCC1187 MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf5TWM2OD1yLkCxPVI1KM7:TR?= NWXTcnNoW0GQR1XS
HCC1599 NH3pS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfVSZQyUUN3ME2wMlAzODJizszN MUjTRW5ITVJ?
ONS-76 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMEKwN|Yh|ryP MkTyV2FPT0WU
KU812 NX3GdmhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe2[YlZUUN3ME2wMlAzODN7IN88US=> MV\TRW5ITVJ?
ML-2 NYDzSVVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jURWlEPTB;MD6wNlA1PyEQvF2= M1nnTHNCVkeHUh?=
HCE-T MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7iUHRKSzVyPUCuNFIxQTJizszN NFXVb3RUSU6JRWK=
NCI-H446 M2LodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEKxNVIh|ryP MnHIV2FPT0WU
RPMI-6666 NEfINmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMEKxOFkh|ryP M2frU3NCVkeHUh?=
MOLT-16 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMEKxOVMh|ryP MX\TRW5ITVJ?
JiyoyeP-2003 M1nwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMEKxO|Yh|ryP M3LJOHNCVkeHUh?=
MHH-PREB-1 M3njbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H5[mlEPTB;MD6wNlE6OSEQvF2= M2juZnNCVkeHUh?=
MC-CAR M33OeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYOzb3NiUUN3ME2wMlAzOzJ4IN88US=> NE\vUmRUSU6JRWK=
BC-3 NUnn[YJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULpdHFKUUN3ME2wMlAzOzR2IN88US=> Mm\MV2FPT0WU
KINGS-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIOzUlVKSzVyPUCuNFI{PTVizszN M{THN3NCVkeHUh?=
PF-382 NFHzcVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XiSGlEPTB;MD6wNlM4QCEQvF2= NF3Bc2NUSU6JRWK=
J-RT3-T3-5 M4LFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEKzPFMh|ryP NVrlSox7W0GQR1XS
SF539 NWXqSIhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHmWo14UUN3ME2wMlAzPDBzIN88US=> NUXtUmw3W0GQR1XS
LB831-BLC MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PQOmlEPTB;MD6wNlQ5PSEQvF2= MmPKV2FPT0WU
DMS-114 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S4eGlEPTB;MD6wNlUxOiEQvF2= NXHKdmh5W0GQR1XS
LB1047-RCC NWfITIU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jIV2lEPTB;MD6wNlUyKM7:TR?= NXrzTZZUW0GQR1XS
LB771-HNC Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LaPWlEPTB;MD6wNlU{PCEQvF2= MUXTRW5ITVJ?
BB65-RCC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEK1N|Qh|ryP MX7TRW5ITVJ?
BV-173 M3XEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEK1OVQh|ryP MUDTRW5ITVJ?
ARH-77 M3HreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHTWXpxUUN3ME2wMlAzPjBzIN88US=> MX;TRW5ITVJ?
IST-MEL1 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z1S2lEPTB;MD6wNlYzOyEQvF2= MlzYV2FPT0WU
NB1 NVHlR4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWwcnpLUUN3ME2wMlAzPjh5IN88US=> MWfTRW5ITVJ?
EoL-1-cell NETJ[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3kTWM2OD1yLkCyOlg5KM7:TR?= NGDNR29USU6JRWK=
KY821 MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHOSIU4UUN3ME2wMlAzPjl5IN88US=> MoTGV2FPT0WU
CMK NETV[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFmyOJZKSzVyPUCuNFI4OzRizszN NGnIfWZUSU6JRWK=
NCI-H2126 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr0Z3lKSzVyPUCuNFI4PjhizszN NGTQRXVUSU6JRWK=
NCI-H526 MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2npSmlEPTB;MD6wNlg6OSEQvF2= MlTyV2FPT0WU
COLO-684 NV\ie2FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEK5NFgh|ryP MnLCV2FPT0WU
NCI-H747 NHjpcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEK5N|Mh|ryP MoXBV2FPT0WU
JAR MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW1UmZKSzVyPUCuNFI6PDZizszN MnnTV2FPT0WU
MEG-01 M2DxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMEK5O|gh|ryP NWnlOmpSW0GQR1XS
MONO-MAC-6 M2jMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXUTWM2OD1yLkCzNFI{KM7:TR?= MY\TRW5ITVJ?
IST-SL1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXPTWM2OD1yLkCzNFQzKM7:TR?= Mkj4V2FPT0WU
CPC-N MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\seWlEPTB;MD6wN|A4QSEQvF2= NXLyTlFJW0GQR1XS
NCI-H1963 NFvKTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEOxN|Eh|ryP Mn7rV2FPT0WU
K052 NXv2TnJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHzSlhKSzVyPUCuNFMzPDdizszN MXPTRW5ITVJ?
KM-H2 NIG1[|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGGyW4pKSzVyPUCuNFM{ODdizszN M1;qSHNCVkeHUh?=
TE-12 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjxbpVlUUN3ME2wMlA{OzB7IN88US=> M4fXWnNCVkeHUh?=
TK10 M{\FS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTsXmtrUUN3ME2wMlA{OzV4IN88US=> NXn2OG5iW0GQR1XS
NMC-G1 M33qS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTFTWM2OD1yLkCzOFUzKM7:TR?= MlL0V2FPT0WU
no-11 NYrpN5RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEO0O|gh|ryP NU[yd4Q1W0GQR1XS
NCI-H524 NVj2NGo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMEO1Nlkh|ryP MljBV2FPT0WU
MHH-CALL-2 NYTBN4JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPKdFdCUUN3ME2wMlA{PTZ{IN88US=> Mm\JV2FPT0WU
GB-1 NGP4VXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LkR2lEPTB;MD6wN|Yh|ryP NF3oTXZUSU6JRWK=
OPM-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPOTWM2OD1yLkCzOlc{KM7:TR?= NGe2RoRUSU6JRWK=
RH-1 MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEO4NVkh|ryP M4KyVXNCVkeHUh?=
NCI-H64 NFrHOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PObGlEPTB;MD6wN|g2PyEQvF2= MoPnV2FPT0WU
EVSA-T M{\F[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHURXNKSzVyPUCuNFM6OjNizszN MYLTRW5ITVJ?
KARPAS-299 M{\4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTuUItPUUN3ME2wMlA{QThizszN NFTkcXpUSU6JRWK=
MZ7-mel Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j1ZWlEPTB;MD6wOFA1KM7:TR?= NYPjUWFkW0GQR1XS
LB373-MEL-D MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7jSXRUUUN3ME2wMlA1OTB3IN88US=> MmX4V2FPT0WU
HEL M2PEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmexTWM2OD1yLkC0NVQh|ryP M4XuUnNCVkeHUh?=
SW872 M2\rXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TMe2lEPTB;MD6wOFIyKM7:TR?= NI\DZXVUSU6JRWK=
DU-4475 NFrkN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PifWlEPTB;MD6wOFI1PCEQvF2= Mkj1V2FPT0WU
IST-SL2 M1fRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXCdWtrUUN3ME2wMlA1Ojd3IN88US=> NWDxT3RuW0GQR1XS
NCI-H82 NEKwTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrsTWM2OD1yLkC0N|A4KM7:TR?= NHX0TFNUSU6JRWK=
LC4-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMESzOVEh|ryP MXHTRW5ITVJ?
HDLM-2 M2nzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf5dnFKSzVyPUCuNFQ{QTJizszN NWjSdYJEW0GQR1XS
MMAC-SF M3jmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvhZllKSzVyPUCuNFQ2OzRizszN M1;5TXNCVkeHUh?=
L-540 NWiwXZZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Lvb2lEPTB;MD6wOFY{QSEQvF2= MV7TRW5ITVJ?
MZ2-MEL MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMES3OFIh|ryP Ml:wV2FPT0WU
LU-134-A MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDKTWM2OD1yLkC0O|c{KM7:TR?= M37RXnNCVkeHUh?=
UACC-257 NUPyVJVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13RZ2lEPTB;MD6wOFg1QSEQvF2= MVvTRW5ITVJ?
NCI-H1581 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMES5OVMh|ryP M4nUSHNCVkeHUh?=
NB17 Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDoUVVKSzVyPUCuNFQ6PzlizszN NHrHd4FUSU6JRWK=
SBC-1 NEG0T3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMEWwOFIh|ryP MX;TRW5ITVJ?
TALL-1 NH7GXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXIVpdWUUN3ME2wMlA2ODR3IN88US=> NYTjOXB2W0GQR1XS
NCI-H1304 M4DWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEWyNFgh|ryP NV3qUItFW0GQR1XS
NEC8 NGqzUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv2OVdKSzVyPUCuNFUzQDZizszN MVrTRW5ITVJ?
CAL-148 M1\MdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7UcHRlUUN3ME2wMlA2PDN7IN88US=> MYDTRW5ITVJ?
CGTH-W-1 NVnpTZNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnIR|NHUUN3ME2wMlA2PDR7IN88US=> MYHTRW5ITVJ?
NCI-H889 Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrhR5lKSzVyPUCuNFU2QTJizszN Mn\4V2FPT0WU
GR-ST NFjrbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrP[mFKSzVyPUCuNFU3OjFizszN M{TKS3NCVkeHUh?=
KARPAS-422 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLQSmQ2UUN3ME2wMlA2PjVizszN Mkm4V2FPT0WU
RPMI-8866 NIe5OpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMEW3NVIh|ryP M13kfnNCVkeHUh?=
SCLC-21H NEfGeXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HwN2lEPTB;MD6wOVg5PCEQvF2= NYH6fmQ6W0GQR1XS
COR-L88 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LWOWlEPTB;MD6wOVkzPyEQvF2= NWK0bYNGW0GQR1XS
LU-139 NGW2S5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrqOJZPUUN3ME2wMlA2QTh4IN88US=> M{PUXXNCVkeHUh?=
SF126 MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHvTWM2OD1yLkC2NVM{KM7:TR?= NX6zSYx4W0GQR1XS
NCI-H1882 NGjNSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwME[0NlQh|ryP M4HWe3NCVkeHUh?=
EW-24 MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HHSmlEPTB;MD6wOlQ5OyEQvF2= M1rNWHNCVkeHUh?=
CP67-MEL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwME[4NUDPxE1? NYj6W4h[W0GQR1XS
DG-75 NFfjZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwME[4PVkh|ryP NVHjNopFW0GQR1XS
LOXIMVI MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMEewNlgh|ryP NITxXHpUSU6JRWK=
HH M{nyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjpVXdKSzVyPUCuNFcyPTdizszN NEX0TlRUSU6JRWK=
K5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7YcWFKSzVyPUCuNFczOjZizszN NHTndZNUSU6JRWK=
EC-GI-10 MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzWTWM2OD1yLkC3NlU4KM7:TR?= NHTw[WRUSU6JRWK=
SK-N-DZ NWjxZ|M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XyXWlEPTB;MD6wO|MxPyEQvF2= NUGwRW1pW0GQR1XS
A3-KAW MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzXdnBKSzVyPUCuNFc{PTFizszN M2rXUnNCVkeHUh?=
MLMA MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu2Om5bUUN3ME2wMlA4PDZ3IN88US=> NGrQbJhUSU6JRWK=
LB996-RCC M1i0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMEe3NFch|ryP MXvTRW5ITVJ?
OS-RC-2 NW\SfIVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:0SGlEPTB;MD6wO|c1QCEQvF2= M3jRRXNCVkeHUh?=
CTB-1 M2DZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\rdpVKSzVyPUCuNFc5OSEQvF2= MkG3V2FPT0WU
IST-MES1 NH3nbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjERVBbUUN3ME2wMlA4QTF{IN88US=> M2fZfHNCVkeHUh?=
LS-1034 MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XIR2lEPTB;MD6wPFA{PSEQvF2= M2[zR3NCVkeHUh?=
HT MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTLNXFUUUN3ME2wMlA5ODh4IN88US=> MmmzV2FPT0WU
NCI-H2141 NF;Te2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;KTWM2OD1yLkC4NUDPxE1? MoS1V2FPT0WU
LB2518-MEL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvHTWM2OD1yLkC4NVQyKM7:TR?= NX;hS4d[W0GQR1XS
GI-ME-N NV3XTYozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHrTWM2OD1yLkC4OFUzKM7:TR?= NVSwXIZoW0GQR1XS
TGW MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMEi2NFch|ryP NFvPVJJUSU6JRWK=
SK-NEP-1 M1L6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPHTWM2OD1yLkC4OlQyKM7:TR?= NUPrRopyW0GQR1XS
NOMO-1 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPvTWM2OD1yLkC5Nlc2KM7:TR?= Ml3xV2FPT0WU
ES6 M1rXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nsOWlEPTB;MD6wPVU5QSEQvF2= NWDOU2Z2W0GQR1XS
NCI-H209 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHDcJpRUUN3ME2wMlA6Pzh4IN88US=> NIPGRm9USU6JRWK=
GAK MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO3R3hKSzVyPUCuNVAyPiEQvF2= MmXCV2FPT0WU
BC-1 NX:5R2h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMUCzOlEh|ryP NIe4VJFUSU6JRWK=
KLE M2POWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnmXY1KSzVyPUCuNVA1PDNizszN NWfuRZZJW0GQR1XS
EW-3 M4PzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvpTWM2OD1yLkGwPVgh|ryP MmnXV2FPT0WU
NKM-1 M4PWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rSe2lEPTB;MD6xNVEh|ryP MXPTRW5ITVJ?
D-336MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPNTWM2OD1yLkGxNlQ1KM7:TR?= NVLBW|BrW0GQR1XS
NB69 NVr0TJpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrrN4VKSzVyPUCuNVE{ODFizszN MnPKV2FPT0WU
D-263MG NFvrbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMUG3NVIh|ryP Moq0V2FPT0WU
KP-N-YS M3rvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMUKyPVEh|ryP NWDTfJF7W0GQR1XS
NCI-H1155 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zjUGlEPTB;MD6xNlU2QCEQvF2= MWfTRW5ITVJ?
BOKU NGrU[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i2e2lEPTB;MD6xNlU4QSEQvF2= M3zXXnNCVkeHUh?=
LAMA-84 M4jEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;ncmtKSzVyPUCuNVI6QSEQvF2= MmLSV2FPT0WU
Raji NEPvdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMUOxNVch|ryP NWniVpZbW0GQR1XS
LU-65 NInxTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMUOzNFch|ryP NVHDZWFUW0GQR1XS
NCI-H187 M1LldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy0NWxXUUN3ME2wMlE{QTJ2IN88US=> NF;JWFBUSU6JRWK=
GCIY NInMcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLQWpp{UUN3ME2wMlE1QTBzIN88US=> NFjRbHZUSU6JRWK=
NCI-H2107 NXr0OnZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMUWwPEDPxE1? NXzkPIh6W0GQR1XS
NCI-H1522 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXqTWM2OD1yLkG1NlY3KM7:TR?= MX7TRW5ITVJ?
NB6 MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojQTWM2OD1yLkG1OlI{KM7:TR?= MnPyV2FPT0WU
EM-2 M3vnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMUW3NFYh|ryP NVe0ToZzW0GQR1XS
HCC2218 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NECwXlJKSzVyPUCuNVU6QCEQvF2= M3HxbnNCVkeHUh?=
NCI-H748 M2rUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[5c2lEPTB;MD6xOlM4PiEQvF2= NF:5d5NUSU6JRWK=
MS-1 M2ruOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XKbWlEPTB;MD6xOlU{PyEQvF2= MVHTRW5ITVJ?
NB5 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XI[mlEPTB;MD6xOlU6PyEQvF2= MoTXV2FPT0WU
OMC-1 NXHWNYh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;xXmlEPTB;MD6xOlY5QCEQvF2= MYDTRW5ITVJ?
NCI-H345 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMU[5Nlgh|ryP MWXTRW5ITVJ?
L-428 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXNZZVKSzVyPUCuNVY6PDVizszN M{KzWnNCVkeHUh?=
SCH NH23bWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLFbJN3UUN3ME2wMlE5Pjh3IN88US=> NF20VnVUSU6JRWK=
NCI-H1417 NHyybHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDXPJBKSzVyPUCuNVkzOjdizszN M1TCbHNCVkeHUh?=
COLO-320-HSR MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LNOWlEPTB;MD6xPVU{OiEQvF2= M3PHTnNCVkeHUh?=
BT-474 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMkC4PVIh|ryP MXvTRW5ITVJ?
GDM-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfkTWM2OD1yLkKxPVcyKM7:TR?= NF3oUm9USU6JRWK=
NCI-H2196 NE\UPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHvNmtKSzVyPUCuNlIzOzVizszN NYftbmM2W0GQR1XS
KP-N-RT-BM-1 NWjafVNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX1TWM2OD1yLkKyN|Q6KM7:TR?= MmftV2FPT0WU
KNS-81-FD MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7BTWM2OD1yLkKyPVU5KM7:TR?= NYPZbFNKW0GQR1XS
COLO-668 M{DyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPBNGZKSzVyPUCuNlM3PzVizszN M3W0NHNCVkeHUh?=
C2BBe1 NGnpSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzQbHZKSzVyPUCuNlY4PDdizszN NYDIRo01W0GQR1XS
Ramos-2G6-4C10 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\hdItKSzVyPUCuNlY6PTRizszN M2H6eXNCVkeHUh?=
CAS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4mybGlEPTB;MD6yO|A6PiEQvF2= M3r2cnNCVkeHUh?=
GOTO NEHYRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\hTWM2OD1yLkK3PFk1KM7:TR?= M1jUPHNCVkeHUh?=
LP-1 M1qwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX0cnpyUUN3ME2wMlI5ODV5IN88US=> MmK4V2FPT0WU
NCI-SNU-1 NHKxN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjxSpdlUUN3ME2wMlI6PDJ{IN88US=> NYTZNoQ{W0GQR1XS
EB-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPyTWM2OD1yLkK5PVc6KM7:TR?= M1nCV3NCVkeHUh?=
MHH-NB-11 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT0fnRpUUN3ME2wMlMxPDB{IN88US=> MYHTRW5ITVJ?
SK-N-FI NIjlfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\OUmlEPTB;MD6zNVY6OiEQvF2= M4TGenNCVkeHUh?=
HCC2157 NI\ycm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETYc4lKSzVyPUCuN|M6OTNizszN NWLOfWVuW0GQR1XS
SIMA MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zibmlEPTB;MD6zOFU5OSEQvF2= NEnGXVFUSU6JRWK=
MDA-MB-134-VI M{jEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPJfmlKSzVyPUCuN|Y6OjhizszN M3u0TXNCVkeHUh?=
NCI-H1694 NEnV[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[4cmlEPTB;MD6zO{DPxE1? M3jMXnNCVkeHUh?=
EHEB NHjmOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwM{mwPFUh|ryP MYfTRW5ITVJ?
U-266 NF\nXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDtTWM2OD1yLkO5PFQ3KM7:TR?= Mkj0V2FPT0WU
LC-1F MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjCeGF6UUN3ME2wMlQ{PzZ3IN88US=> MlzuV2FPT0WU
SHP-77 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;rUIpKSzVyPUCuOFc5PTVizszN MorwV2FPT0WU
LS-513 NVywWZZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3sfVEyUUN3ME2wMlQ6OzB5IN88US=> NYTVOI5UW0GQR1XS

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度: 0.1-100 pM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験:

[5]

+ 展開
  • 動物モデル: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量: 20 mg/kg
  • 投与方法: Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
2.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管
in solvent
別名 NSC 125973

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 質問2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associatedシグナル伝達経路

相関Microtubule Associated製品

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID